Earlier this month, the Times reported that the last-minute fiscal cliff deal passed by the Senate included a provision that would delay Medicare price controls on certain drugs used in kidney dialysis, including Sensipar. Most senators did not know about the earmark, which was apparently added by aides just before the final vote and will cost the federal government $500 million. Sensipar is made by Amgen. In addition to being the world’s largest biotechnology corporation, Amgen is also a campaign contributor to Senate Finance Committee chairman Max Baucus (D–MT,) Senate Minority Leader Mitch McConnell (R–KY) and Finance Committee member Orrin Hatch (R–UT.) The company’s registered lobbyists included former chiefs of staff for both Baucus and McConnell.